Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ACT-777991 in Healthy Subjects
NCT04798209Phase 1Completed
- Sponsor
- Idorsia
- Start
- Jan 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ACT-777991 in type 1 diabetes mellitus (T1D) (15 arms), sponsored by Idorsia. Primary endpoint: Incidence of treatment-emergent adverse events. Started Jan 2021; status: completed.
02
Drugs
ACT-777991
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04798209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04798209.